This is a routine refinancing that extends maturity profiles and likely improves pricing terms versus the prior facility. The transaction does not change Teleflex's total debt or equity. Monitor upcoming quarterly filings for the impact of the pending Acute Care and OEM divestitures (announced Dec 2025) on leverage and the new covenant headroom.
Price Chart
Executive Summary
Teleflex refinanced its existing credit facility by entering into a new $2.2 billion Credit Agreement on May 26, 2026. The new facility includes a $1.0 billion five-year revolving credit facility (maturing May 2031), a $500 million term A-1 loan (maturing May 2031), and a $700 million term A-2 loan (maturing May 2028). The agreement refinances the prior November 2022 credit agreement and contains financial covenants requiring a maximum total net leverage ratio of 4.50x and a minimum interest coverage ratio of 3.00x, with customary terms for a large, investment-grade credit profile medical device company.
Key Financial Metrics
Key Facts
- Total new credit commitments of $2.2 billion: $1.0B revolver, $500M Term A-1, $700M Term A-2
- Revolver and Term A-1 mature May 26, 2031 (5-year); Term A-2 matures May 26, 2028
- Interest rates: Term SOFR + 1.125%-2.00% or ABR + 0.125%-1.00% based on leverage/ratings
- Financial covenants: max total net leverage ratio 4.50x; min interest coverage ratio 3.00x
- Refinances the prior Third Amended and Restated Credit Agreement dated Nov 4, 2022
- Secured by substantially all domestic material subsidiary assets and pledges of equity
Financial Impact
Refinancing of $2.2 billion in credit facilities. Proceeds used to repay existing indebtedness. No new incremental borrowing or change in total debt size disclosed.
Risk Factors
- Pending divestitures of Acute Care and OEM businesses could temporarily increase leverage post-closing
- Future use of the $700M Term A-2 (maturing 2028) creates a refinancing risk in ~2 years
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-242184 |
| Document: d126197d8k.htm | 0001193125-26-242184 |
| Document: 0001193125-26-242184-index-headers.html | 0001193125-26-242184 |
| Document: 0001193125-26-242184-index.html | 0001193125-26-242184 |
| Document: 0001193125-26-242184.txt | 0001193125-26-242184 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $138.89 $139.96 | ▲ +0.77% | ▲ +0.17% | $124.12 (−10.63%) |
Jul 2, 2026 13w ago | Court Ruling | $133.99 $132.30 | ▼ −1.26% | ▼ −0.85% | $124.12 (−7.37%) |
Jun 22, 2026 14w ago | Institutional Cluster | $121.67 $134.61 | ▲ +10.64% | ▲ +10.78% | $124.12 (+2.01%) |
Jun 15, 2026 15w ago | 8-K | $127.87 $130.16 | ▲ +1.79% | ▲ +1.59% | $124.12 (−2.93%) |
Jun 9, 2026 16w ago | 8-K | $132.15 $134.04 | ▲ +1.43% | ▼ −2.19% | $124.12 (−6.08%) |
Jun 1, 2026 17w ago | 8-K | $127.31 $127.49 | ▲ +0.14% | ▲ +2.45% | $124.12 (−2.51%) |
May 27, 2026 18w ago | 8-K | $128.90 $127.79 | ▼ −0.86% | ▲ +1.83% | $124.12 (−3.71%) |
May 7, 2026 21w ago | 8-K | $131.59 $128.56 | ▼ −2.31% | ▼ −5.44% | $124.12 (−5.68%) |
Feb 26, 2026 31w ago | 8-K | $118.39 $110.38 | ▼ −6.77% | ▼ −0.36% | $124.12 (+4.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access